Afferent

Attenua

This company develops small-molecule medicines for patients suffering from chronic respiratory disorders, particularly chronic cough.

Escient Pharmaceuticals

This company develops small molecule therapeutics for patients with neurosensory-inflammatory disorders, such as chronic urticaria, atopic dermatitis and cholestatic pruritus.

Addex Therapeutics

This biopharmaceutical company develops oral small molecule allosteric modulators for patients with neurological disorders, including addiction, Parkinson's disease, and chronic cough.

Vicore Pharma

This clinical-stage biopharmaceutical company develops angiotensin II type 2 receptor agonists to treat patients with idiopathic pulmonary fibrosis and other rare lung diseases.

Melius Pharma

The company develops pharmaceutical treatments for chronic cough in patients with idiopathic pulmonary fibrosis.

AirNexis Therapeutics

This company develops inhaled small molecule medicines to treat chronic obstructive pulmonary disease for patients with respiratory conditions.

SiteOne

This biopharmaceutical company develops selective small molecule sodium channel inhibitors to treat patients with pain, cough and other hypersensitivity disorders.

Calluna Pharma

This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.